A Phase 1 Study of Oral LOXO-292 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs LOXO 292 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Loxo Oncology
- 10 May 2017 Status changed from planning to recruiting, according to a Loxo Oncology media release.
- 19 Dec 2016 According to a Loxo Oncology media release, clinical data from this trial is expected by year end 2017.
- 15 Nov 2016 New trial record